banner technology

Intellectual Property

The CyTuVax technology is protected by a new patent "Composition comprising cytokine macro-aggregates" PCT/EP2013/072865 with priority date 06-11-2013. The patent received an excellent evaluation report from the International Examining Authority of the European Patent Office in July 2014, stating no objections on all the 17 claims for novelty, inventive steps and industrial applicability. In May 2015, the patent has been registered. Next to the approved patent, CyTuVax’ vaccination technology is protected by proprietary methods for adjuvant manufacturing (cytokine-depot binding).

Latest news

showCyTuVax is currently testing its vaccine technology in a clinical Phase 2 study of a vaccine for hepatitis B non-responders

Where we are

About us

CyTuVax B.V.
Oxfordlaan 55
6229 EV Maastricht
The Netherlands

This email address is being protected from spambots. You need JavaScript enabled to view it.